Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.63 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | AMD1 | P17707 | 2/20 | 0.51 |
| ▸ | PRKACA | P17612 | 4/20 | 0.49 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970657 | 1.00 | PI4KA (0.63) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13662859 | 0.97 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL17109960 | 0.89 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9936952 | 0.88 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13664461 | 0.87 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9915107 | 0.86 | PRMT5 (0.47) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9941051 | 0.86 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9941044 | 0.86 | PI4KA (0.62) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL17108373 | 0.86 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL17773142 | 0.86 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. | 2016-03-10 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029343-B2 | Modulators of histone methyltransferase, and methods of use thereof | Epizyme, Inc. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | Epizyme, Inc. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2646455-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082436-A2 | MODULATORS OF HISTONE METHYLTRANSFERASE, AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068559-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885 |
| US-20130310333-A1 | Modulators of Histone Methyltransferase, and Methods of Use Thereof | EHMT1, EHMT2, HNMT | PI4KA 1844/4885PI4K2B 1901/4885PI4K2A 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.